The studies of PLGA nanoparticles loading Atorvastatin calcium (cas 134523-03-8) for oral administration in vitro and in vivo
-
Add time:07/31/2019 Source:sciencedirect.com
A biodegradable poly(lactic-co-glycolic acid) loading Atorvastatin calcium (cas 134523-03-8) (AC) nanoparticles (AC-PLGA-NPs) were prepared by probe ultrasonication and evaporation method aiming at improving the oral bioavailability of AC. The effects of experimental parameters, including stabilizer species, stabilizer concentration and pH of aqueous phase, on particle size were also evaluated. The resultant nanoparticles were in spherical shape with an average diameter of 174.7 nm and a narrow particle size distribution. And the drug loading and encapsulation efficiency were about 8% and 71%, respectively. The particle size and polydispersion were almost unchanged in 10 days. The release curves of AC-PLGA-NPs in vitro displaying sustained release characteristics indicated that its release mechanisms were matrix erosion and diffusion. The pharmacokinetic study in vivo revealed that the Cmax and AUC0-∞ of AC-PLGA-NPs in rats were nearly 3.7-fold and 4.7-fold higher than that of pure atorvastatin calcium suspension. Our results demonstrated that the delivery of AC-PLGA-NPs could be a promising approach for the oral delivery of AC for enhanced bioavailability.
We also recommend Trading Suppliers and Manufacturers of Atorvastatin calcium (cas 134523-03-8). Pls Click Website Link as below: cas 134523-03-8 suppliers
Prev:Preparation, characterization, and in vitro/vivo evaluation of polymer-assisting formulation of Atorvastatin calcium (cas 134523-03-8) based on solid dispersion technique
Next:Novel sublingual tablets of Atorvastatin calcium (cas 134523-03-8)/Trimetazidine hydrochloride combination; HPTLC quantification, in vitro formulation and characterization) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Physicochemical characteristics of the complexes of simvastatin and Atorvastatin calcium (cas 134523-03-8) with hydroxypropyl-β-cyclodextrin produced by mechanochemical activation08/06/2019
- Development and validation of RP-HPLC method for determination of Atorvastatin calcium (cas 134523-03-8) and Nicotinic acid in combined tablet dosage form08/05/2019
- Atorvastatin calcium (cas 134523-03-8) in combination with methylprednisolone for the treatment of multiple sclerosis relapse08/04/2019
- UHPLC-MS/MS method for determination of Atorvastatin calcium (cas 134523-03-8) in human plasma: Application to a pharmacokinetic study based on healthy volunteers with specific genotype08/03/2019
- Chemically modified carbon paste ion-selective electrodes for determination of Atorvastatin calcium (cas 134523-03-8) in pharmaceutical preparations08/02/2019
- Novel sublingual tablets of Atorvastatin calcium (cas 134523-03-8)/Trimetazidine hydrochloride combination; HPTLC quantification, in vitro formulation and characterization08/01/2019
- Preparation, characterization, and in vitro/vivo evaluation of polymer-assisting formulation of Atorvastatin calcium (cas 134523-03-8) based on solid dispersion technique07/30/2019
-
Health and Chemical more >
-
Related Products
- Atorvastatin Acyl-b-D-glucuronide
- Atorvastatin calcium
- Atorvastatin lactone
- Atorvastatin sodium salt
- Atorvastatin tert-Butyl Ester
- Calcium valproate
- Calcium (1)-bis(2-hydroxy-4-methylvalerate)
- Calcium (2S)-2-[(4-chlorobenzoyl)amino]-3-(1H-indol-3-yl)propanoate
- Calcium (S)-3-methyl-2-oxovalerate
- Calcium 2,4-dichlorophenolate